Clinical significance of HER2 in urothelial carcinoma and analysis of its correlation with glycolytic metabolic characteristics by Andong Guo, Andong Guo, Chenrui Wu, Jishuang Cao, Kejia Zhu, Kejia Zhu, Sentai Ding, Sentai Ding

Get full text

Immune checkpoint inhibitor therapy as a neoadjuvant treatment for muscle-invasive bladder carcinoma: A narrative review by Sentai Ding, Chenrui Wu, Jishuang Cao, Jiaju Lyu

Get full text

Efficacy and safety of Tislelizumab combined with Axitinib as first-line treatment for intermediate- and high-risk metastatic clear-cell renal cell carcinoma by Jie Cui, Pengyong Xu, Changying Guo, Changying Guo, Yong Guan, Yong Guan, Kejia Zhu, Kejia Zhu, Sentai Ding, Sentai Ding

Get full text

A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer. by Liang Sun, Jiaju Lu, Zhihong Niu, Kejia Ding, Dongbin Bi, Shuai Liu, Jiamei Li, Fei Wu, Hui Zhang, Zuohui Zhao, Sentai Ding

Get full text